Want to see SE:FLUO full AI Analyst Report?

FluoGuide A/S (FLUO) Price & Analysis

1 Followers

FLUO Stock Chart & Stats

kr32.50

-kr1.20(-3.69%)

At close: Jul 27 4:00 PM EDT

kr32.50

-kr1.20(-3.69%)

Day’s Range― - ―

52-Week Rangekr28.00 - kr47.80

Previous CloseN/A

Volume5.16K

Average Volume (3M)8.21K

Market Cap

kr524.81M

Enterprise Valuekr427.89M

Total Cash (Recent Filing)kr63.24M

Total Debt (Recent Filing)kr27.93M

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Aug 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.89

Shares Outstanding16,349,314

10 Day Avg. Volume11,579

30 Day Avg. Volume8,206

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)6.10

Price to Sales (P/S)0.00

P/FCF Ratio-8.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.98

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet CushionThe company still reports positive equity and a moderate debt-to-equity ratio, providing a financial cushion versus peers. That balance-sheet flexibility can fund near-term clinical programs or absorb shocks, preserving optionality while management pursues commercialization or partnerships.

Specialized Clinical FocusFluoGuide's core focus on targeted fluorescent imaging agents for fluorescence-guided surgery addresses a clear clinical need in oncology operations. This specialized, hard-to-replicate product focus supports durable competitive differentiation and potential for long-term adoption by surgical oncology centers and partners.

Improving Cash Burn TrendReported free cash flow improved versus the prior annual period, suggesting progress on cost control or program scaling. A sustained reduction in burn extends runway, reduces near-term financing urgency, and gives management time to reach clinical or commercialization milestones that materially change funding needs.

Bears Say

High Cash BurnMaterial negative operating and free cash flow indicate the company currently cannot self-fund its operations or clinical programs. Persistent high burn forces repeated external financing, increasing dilution risk and potentially delaying program timelines if capital markets tighten or partnership milestones slip.

Minimal, Volatile RevenueRevenue is extremely low and highly volatile, most recently collapsing to near-zero annual sales. Without predictable product sales or recurring licensing income, the business remains dependent on external funding or milestone payments, leaving commercialization and scalability unproven for the near term.

Operating Losses Eroding EquityOperating losses far exceed any sales and have reduced shareholders' equity materially year-over-year. Continued negative returns on equity and capital erosion weaken financial resilience, raise refinancing risk, and could limit strategic choices like partnering or investing in commercialization without fresh capital.

FluoGuide A/S News

FluoGuide’s FG001 Phase 2 Trial Targets Sharper Brain Tumor Surgery and New Value for Investors

FluoGuide A/S ($SE:FLUO) announced an update on their ongoing clinical study. FluoGuide A/S (FLUO) is launching a Phase...

2M ago

FLUO

FLUO FAQ

What was FluoGuide A/S’s price range in the past 12 months?

FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.80 in the past 12 months.

What is FluoGuide A/S’s market cap?

FluoGuide A/S’s market cap is kr524.81M.

When is FluoGuide A/S’s upcoming earnings report date?

FluoGuide A/S’s upcoming earnings report date is Aug 25, 2026 which is in 27 days.

How were FluoGuide A/S’s earnings last quarter?

FluoGuide A/S released its earnings results on May 27, 2026. The company reported -kr1.032 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.032.

Is FluoGuide A/S overvalued?

According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FluoGuide A/S pay dividends?

FluoGuide A/S does not currently pay dividends.

What is FluoGuide A/S’s EPS estimate?

FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FluoGuide A/S have?

FluoGuide A/S has 16,349,314 shares outstanding.

What happened to FluoGuide A/S’s price movement after its last earnings report?

FluoGuide A/S reported an EPS of -kr1.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.687%.

Which hedge fund is a major shareholder of FluoGuide A/S?

Currently, no hedge funds are holding shares in SE:FLUO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FluoGuide A/S

FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.